Benzinga | Sep 7, 2021 11:29AM EDT

Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab

* Amgen Inc (NASDAQ:AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication of respiratory disease.

* New data demonstrated that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.

* Amgen is developing Tezepelumab in collaboration with AstraZeneca plc (NASDAQ:AZN).

* At the 52-week mark, tezepelumab patients showed the annualized rate of asthma exacerbations was 0.39, compared to 2.76 in the placebo group.

* The difference amounted to an 86% reduction in exacerbations.

* The rate of exacerbations in patients without nasal polyps fell 52%, with the annualized rates in the tezepelumab and placebo groups clocking in at 0.98 and 2.05, respectively.

* Amgen and AstraZeneca secured priority review at the FDA earlier this year, putting them on course to win approval for the thymic stromal lymphopoietin inhibitor in Q1 of 2022.

* Related Content: Amgen - AstraZeneca's Asthma Candidate Under Priority Review With FDA.

* Price Action: AMGN stock is down 2.57% at $220.55, while AZN shares are down 0.98% at $58.25 during the market session on the last check Tuesday.